Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2022

01-12-2022 | Idiopathic Pulmonary Fibrosis | Research

The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study

Authors: L. Plantier, A. Smolinska, R. Fijten, M. Flamant, J. Dallinga, J. J. Mercadier, D. Pachen, M. P. d’Ortho, F. J. van Schooten, B. Crestani, A. W. Boots

Published in: Respiratory Research | Issue 1/2022

Login to get access

Abstract

Background

Fibrotic Interstitial lung diseases (ILD) are a heterogeneous group of chronic lung diseases characterized by diverse degrees of lung inflammation and remodeling. They include idiopathic ILD such as idiopathic pulmonary fibrosis (IPF), and ILD secondary to chronic inflammatory diseases such as connective tissue disease (CTD). Precise differential diagnosis of ILD is critical since anti-inflammatory and immunosuppressive drugs, which are beneficial in inflammatory ILD, are detrimental in IPF. However, differential diagnosis of ILD is still difficult and often requires an invasive lung biopsy. The primary aim of this study is to identify volatile organic compounds (VOCs) patterns in exhaled air to non-invasively discriminate IPF and CTD-ILD. As secondary aim, the association between the IPF and CTD-ILD discriminating VOC patterns and functional impairment is investigated.

Methods

Fifty-three IPF patients, 53 CTD-ILD patients and 51 controls donated exhaled air, which was analyzed for its VOC content using gas chromatograph- time of flight- mass spectrometry.

Results

By applying multivariate analysis, a discriminative profile of 34 VOCs was observed to discriminate between IPF patients and healthy controls whereas 11 VOCs were able to distinguish between CTD-ILD patients and healthy controls. The separation between IPF and CTD-ILD could be made using 16 discriminating VOCs, that also displayed a significant correlation with total lung capacity and the 6 min’ walk distance.

Conclusions

This study reports for the first time that specific VOC profiles can be found to differentiate IPF and CTD-ILD from both healthy controls and each other. Moreover, an ILD-specific VOC profile was strongly correlated with functional parameters. Future research applying larger cohorts of patients suffering from a larger variety of ILDs should confirm the potential use of breathomics to facilitate fast, non-invasive and proper differential diagnosis of specific ILDs in the future as first step towards personalized medicine for these complex diseases.
Literature
1.
Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. Eur Respir Rev. 2014;23(131):40–54.PubMed
2.
American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.
3.
4.
Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136(5):1397–405.PubMedPubMedCentral
5.
Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014;146(2):422–36.PubMed
6.
Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117(3):524–9.PubMedPubMedCentral
7.
8.
Meiners S, Eickelberg O, Konigshoff M. Hallmarks of the ageing lung. Eur Respir J. 2015;45(3):807–27.PubMed
9.
Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(8):838–46.PubMedPubMedCentral
10.
Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010;12(4):213.PubMedPubMedCentral
11.
Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380(9842):689–98.PubMed
12.
Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ, Clinical IPF. Prednisone, azathioprine, and n-acetylcysteine for pulmonary fibrosis. New Engl J Med. 2012;366(21):1968–77.PubMed
13.
Macagno F, Varone F, Leone PM, Mari PV, Panico L, Berardini L, et al. New treatment directions for IPF: current status of ongoing and upcoming clinical trials. Expert Rev Respir Med. 2017;11(7):533–48.PubMed
14.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.PubMed
15.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.PubMed
16.
Canestaro WJ, Forrester SH, Raghu G, Ho L, Devine BE. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. Chest. 2016;149(3):756–66.PubMed
17.
Torrisi SE, Kahn N, Walscher J, Sarmand N, Polke M, Lars K, et al. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. BMC Pulm Med. 2019;19(1):213.PubMedPubMedCentral
18.
Heukels P, Moor CC, von der Thusen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79–91.PubMed
19.
Ubieta K, Thomas MJ, Wollin L. The effect of nintedanib on T-Cell activation, subsets and functions. Drug Des Devel Ther. 2021;15:997–1011.PubMedPubMedCentral
20.
Bryson T, Sundaram B, Khanna D, Kazerooni EA. Connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonia: similarity and difference. Semin Ultrasound CT MR. 2014;35(1):29–38.PubMed
21.
Martinez FJ, Flaherty KR. Comprehensive and individualized patient care in idiopathic pulmonary fibrosis: refining approaches to diagnosis, prognosis, and treatment. Chest. 2017;151(5):1173–4.PubMed
22.
Hodnett PA, Naidich DP. Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature. Am J Respir Crit Care Med. 2013;188(2):141–9.PubMed
23.
Wells AU, Kokosi MA. Subclinical interstitial lung abnormalities: toward the early detection of idiopathic pulmonary fibrosis? Am J Respir Crit Care Med. 2016;194(12):1445–6.PubMedPubMedCentral
24.
Boots AW, van Berkel JJ, Dallinga JW, Smolinska A, Wouters EF, van Schooten FJ. The versatile use of exhaled volatile organic compounds in human health and disease. J Breath Res. 2012;6(2):027108.PubMed
25.
Boots AW, Bos LD, van der Schee MP, van Schooten FJ, Sterk PJ. Exhaled Molecular Fingerprinting in Diagnosis and Monitoring: Validating Volatile Promises. Trends Mol Med. 2015;21(10):633–44.PubMed
26.
Van Berkel JJ, Dallinga JW, Moller GM, Godschalk RW, Moonen E, Wouters EF, et al. Development of accurate classification method based on the analysis of volatile organic compounds from human exhaled air. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;861(1):101–7.PubMed
27.
Smolinska A, Hauschild AC, Fijten RR, Dallinga JW, Baumbach J, van Schooten FJ. Current breathomics–a review on data pre-processing techniques and machine learning in metabolomics breath analysis. J Breath Res. 2014;8(2):027105.PubMed
28.
Smolinska A, Klaassen EM, Dallinga JW, van de Kant KD, Jobsis Q, Moonen EJ, et al. Profiling of volatile organic compounds in exhaled breath as a strategy to find early predictive signatures of asthma in children. PLoS ONE. 2014;9(4):e95668.PubMedPubMedCentral
29.
Dallinga JW, Robroeks CM, van Berkel JJ, Moonen EJ, Godschalk RW, Jobsis Q, et al. Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children. Clin Exp Allergy. 2010;40(1):68–76.PubMed
30.
Schnabel R, Fijten R, Smolinska A, Dallinga J, Boumans ML, Stobberingh E, et al. Analysis of volatile organic compounds in exhaled breath to diagnose ventilator-associated pneumonia. Sci Rep. 2015;5:17179.PubMedPubMedCentral
31.
Van Berkel JJ, Dallinga JW, Moller GM, Godschalk RW, Moonen EJ, Wouters EF, et al. A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med. 2010;104(4):557–63.PubMed
32.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.PubMed
33.
Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35–45.PubMed
34.
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–68.PubMed
35.
36.
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68.PubMed
37.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.
38.
Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1384–7.PubMed
39.
Box G. Signal-to-Noise Ratios, Performance Criteria, and Transformations. Technometrics. 1988;30(1):1–17.
40.
41.
42.
Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem. 2006;78(13):4281–90.PubMed
43.
Breiman L. Random forests. Mach Learn. 2001;45(1):5–32.
44.
Blanchet L, Smolinska A, Baranska A, Tigchelaar E, Swertz M, Zhernakova A, et al. Factors that influence the volatile organic compound content in human breath. J Breath Res. 2017;11(1):016013.PubMed
45.
Engel J, Blanchet L, Bloemen B, van den Heuvel LP, Engelke UH, Wevers RA, et al. Regularized MANOVA (rMANOVA) in untargeted metabolomics. Anal Chim Acta. 2015;899:1–12.PubMed
46.
Thompson B. Canonical correlation analysis. Encyclopedia of statistics in behavioral sciences. Chicester: John Wiley and Sons Ltd; 2005.
47.
Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met. 1995;57(1):289–300.
48.
Smolinska A, Posma JM, Blanchet L, Ampt KA, Attali A, Tuinstra T, et al. Simultaneous analysis of plasma and CSF by NMR and hierarchical models fusion. Anal Bioanal Chem. 2012;403(4):947–59.PubMedPubMedCentral
49.
Guiot J, Moermans C, Henket M, Corhay JL, Louis R. Blood Biomarkers in Idiopathic Pulmonary Fibrosis. Lung. 2017;195(3):273–80.PubMedPubMedCentral
50.
Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med. 2009;15(9):1077–81.PubMedPubMedCentral
51.
Agarwal R, Zaidi SI, Athar M, Bickers DR, Mukhtar H. Photodynamic effects of chloroaluminum phthalocyanine tetrasulfonate are mediated by singlet oxygen: in vivo and in vitro studies utilizing hepatic microsomes as a model membrane source. Arch Biochem Biophys. 1992;294(1):30–7.PubMed
52.
Adams TB, Cohen SM, Doull J, Feron VJ, Goodman JI, Marnett LJ, et al. The FEMA GRAS assessment of cinnamyl derivatives used as flavor ingredients. Food Chem Toxicol. 2004;42(2):157–85.PubMed
53.
Andersen A. Final report on the safety assessment of benzaldehyde. Int J Toxicol. 2006;25(Suppl 1):11–27.PubMed
54.
Lin Z, Li H, Luo H, Zhang Y, Luo W. Benzylamine and methylamine, substrates of semicarbazide-sensitive amine oxidase, attenuate inflammatory response induced by lipopolysaccharide. Int Immunopharmacol. 2011;11(8):1079–89.PubMed
55.
Singh B, Tschernig T, van Griensven M, Fieguth A, Pabst R. Expression of vascular adhesion protein-1 in normal and inflamed mice lungs and normal human lungs. Virchows Arch. 2003;442(5):491–5.PubMed
56.
Jarnicki AG, Schilter H, Liu G, Wheeldon K, Essilfie AT, Foot JS, et al. The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model. Br J Pharmacol. 2016;173(22):3161–75.PubMedPubMedCentral
57.
Marttila-Ichihara F, Elima K, Auvinen K, Veres TZ, Rantakari P, Weston C, et al. Amine oxidase activity regulates the development of pulmonary fibrosis. FASEB J. 2017;31(6):2477–91.PubMed
58.
Deetz JS, Luehr CA, Vallee BL. Human liver alcohol dehydrogenase isozymes: reduction of aldehydes and ketones. Biochemistry. 1984;23(26):6822–8.PubMed
59.
Kneepkens CM, Ferreira C, Lepage G, Roy CC. The hydrocarbon breath test in the study of lipid peroxidation: principles and practice. Clin Invest Med. 1992;15(2):163–86.PubMed
60.
Kneepkens CM, Lepage G, Roy CC. The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radic Biol Med. 1994;17(2):127–60.PubMed
61.
Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Kloss R, et al. Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta. 2008;393(2):76–84.PubMedPubMedCentral
62.
Phillips M, Cataneo RN, Condos R, Ring Erickson GA, Greenberg J, La Bombardi V, et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb). 2007;87(1):44–52.
63.
Guan XL, Wu PF, Wang S, Zhang JJ, Shen ZC, Luo H, et al. Dimethyl sulfide protects against oxidative stress and extends lifespan via a methionine sulfoxide reductase A-dependent catalytic mechanism. Aging Cell. 2017;16(2):226–36.PubMed
64.
Ostrovsky YuM. Endogenous ethanol–its metabolic, behavioral and biomedical significance. Alcohol. 1986;3(4):239–47.PubMed
65.
Bast A, Weseler AR, Haenen GR, den Hartog GJ. Oxidative stress and antioxidants in interstitial lung disease. Curr Opin Pulm Med. 2010;16(5):516–20.PubMed
66.
Bos LD, Meinardi S, Blake D, Whiteson K. Bacteria in the airways of patients with cystic fibrosis are genetically cap. J Breath Res. 2016;10(4):047103.PubMed
67.
Gupta S, Shariff M, Chaturvedi G, Sharma A, Goel N, Yadav M, et al. Comparative analysis of the alveolar microbiome in COPD, ECOPD, Sarcoidosis, and ILD patients to identify respiratory illnesses specific microbial signatures. Sci Rep. 2021;11(1):3963.PubMedPubMedCentral
68.
Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2(7):548–56.PubMedPubMedCentral
69.
Guilleminault L, Saint-Hilaire A, Favelle O, Caille A, Boissinot E, Henriet AC, et al. Can exhaled nitric oxide differentiate causes of pulmonary fibrosis? Respir Med. 2013;107(11):1789–96.PubMed
70.
Malerba M, Radaeli A, Ragnoli B, Airo P, Corradi M, Ponticiello A, et al. Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement. Chest. 2007;132(2):575–80.PubMed
71.
Tiev KP, Cabane J, Aubourg F, Kettaneh A, Ziani M, Mouthon L, et al. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J. 2007;30(1):26–30.PubMed
72.
Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395–417.PubMed
73.
Bartoli ML, Novelli F, Costa F, Malagrino L, Melosini L, Bacci E, et al. Malondialdehyde in exhaled breath condensate as a marker of oxidative stress in different pulmonary diseases. Mediators Inflamm. 2011;2011:891752.PubMedPubMedCentral
74.
Rihak V, Zatloukal P, Chladkova J, Zimulova A, Havlinova Z, Chladek J. Nitrite in exhaled breath condensate as a marker of nitrossative stress in the airways of patients with asthma, COPD, and idiopathic pulmonary fibrosis. J Clin Lab Anal. 2010;24(5):317–22.PubMedPubMedCentral
75.
Psathakis K, Mermigkis D, Papatheodorou G, Loukides S, Panagou P, Polychronopoulos V, et al. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. Eur J Clin Invest. 2006;36(5):362–7.PubMed
76.
Gaugg MT, Engler A, Bregy L, Nussbaumer-Ochsner Y, Eiffert L, Bruderer T, et al. Molecular breath analysis supports altered amino acid metabolism in idiopathic pulmonary fibrosis. Respirology. 2019;24(5):437–44.PubMed
77.
Yanagihara T, Kolb M. Molecular breath analysis for IPF: Can we make a few breaths count? Respirology. 2019;24(5):404–5.PubMed
78.
79.
Hayton C, Terrington D, Wilson AM, Chaudhuri N, Leonard C, Fowler SJ. Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review. Respir Res. 2019;20(1):7.PubMedPubMedCentral
80.
Kanoh S, Kobayashi H, Motoyoshi K. Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases. Chest. 2005;128(4):2387–92.PubMed
81.
Yamada YI, Yamada G, Otsuka M, Nishikiori H, Ikeda K, Umeda Y, et al. Volatile organic compounds in exhaled breath of idiopathic pulmonary fibrosis for discrimination from healthy subjects. Lung. 2017;195(2):247–54.PubMed
82.
Maher TM. Precision medicine in idiopathic pulmonary fibrosis. Qjm-Int J Med. 2016;109(9):585–7.
83.
Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):141.PubMedPubMedCentral
Metadata
Title
The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study
Authors
L. Plantier
A. Smolinska
R. Fijten
M. Flamant
J. Dallinga
J. J. Mercadier
D. Pachen
M. P. d’Ortho
F. J. van Schooten
B. Crestani
A. W. Boots
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2022
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-021-01923-5

Other articles of this Issue 1/2022

Respiratory Research 1/2022 Go to the issue

Review

Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery

Research

Clinical phenotyping in sarcoidosis using cluster analysis

Research

Impact of chronic obstructive pulmonary disease on short-term outcome in patients with ST-elevation myocardial infarction during COVID-19 pandemic: insights from the international multicenter ISACS-STEMI registry

Research

1-year quality of life and health-outcomes in patients hospitalised with COVID-19: a longitudinal cohort study

Research

Clinical and cytokine patterns of uncontrolled asthma with and without comorbid chronic rhinosinusitis: a cross-sectional study

Research

Physiological response to prone positioning in intubated adults with COVID-19 acute respiratory distress syndrome: a retrospective study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits